Lupin, one of India’s largest generic drug producers, has agreed to purchase Temmler Pharma’s specialty product portfolio. Temmler is based out of Germany. The deal’s amount has yet to be disclosed. Temmler specializes in specialty products treating central nervous system disorders in addition to rare diseases such as Myasthenia Gravis and Huntington disease. This purchase mark’s Lupin’s 4th oversees acquisition in 2015.